1
|
Cheng AQ, Liu Z, Zhao L, Zhou XM, Cui ZY, Qin R, Li JX, Wei XW, Xiao D, Wang C. [Effect evaluation of "Smoking cessation: Doctor first"program in China]. Zhonghua Yi Xue Za Zhi 2022; 102:94-99. [PMID: 35701086 DOI: 10.3760/cma.j.cn112137-20211119-02582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the effect of "Smoking cessation: Doctor first" program on smoking medical staff. Methods: From December 2016 to September 2019, 1 747 smoking medical staff from 54 units of China Tobacco Cessation Alliance were enrolled into"Smoking cessation: Doctor first"program. Demographic characteristics, smoking characteristics, degree of tobacco dependence, willingness to quit smoking and other related factors were collected during the baseline survey. Multivariate logistic regression model was used to analyze the related factors of willingness to quit. The subjects were given intensive smoking cessation intervention from October 2017 to September 2019, including education on the hazards of smoking, methods of smoking cessation and giving smoking cessation drugs. After intervention, the subjects were investigated about their smoking cessation progress and the effect of the project was evaluated. Results: The subjects were (41±11) years old, 91.9% (1 609/1 747) were male and 62.2% (1 086/1 747) were daily smokers. The main reasons for smoking included the influence of friends [697 (39.9%)], the need for social entertainment [629 (36.0%)], the relief of mental stress [589 (33.7%)] and the refreshment [459 (26.3%)]. At baseline, 52.9% (885/1 672) and 43.2% (755/1 747) smokers had intention to quit smoking and had planned to quit within one year, respectively. Multivariate logistic regression model analysis showed that: low education level [OR (95%CI) of high school and junior high school and below were 2.42 (1.61, 3.63) and 1.57 (1.18, 2.11)], daily smoking [OR (95%CI): 1.38 (1.06, 1.78)], thinking quitting smoking is not important [OR (95%CI): 4.15 (3.33, 5.18)] and having no quitting experience [OR (95%CI): 3.21 (2.53, 4.05)] were associated with no intention to quit smoking. After intensive smoking cessation intervention, 81.0% (1 415/1 747) smokers started to quit and 36.6% (518/1 415) quit smoking with drugs, both higher than the baseline level (all P values<0.001). By the end of the program, 60.2% (852/1 415) of the medical staff had quit smoking successfully. Conclusion: "Smoking cessation: Doctor first"program can improve the willingness to quit and the proportion of using smoking cessation drugs of medical staff.
Collapse
Affiliation(s)
- A Q Cheng
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - Z Liu
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - L Zhao
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - X M Zhou
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - Z Y Cui
- Graduate School of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing 100730, China
| | - R Qin
- Graduate School of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing 100730, China
| | - J X Li
- China-Japan Friendship School of Clinical Medicine, Graduate School of Capital Medical University, Beijing 100029, China
| | - X W Wei
- China-Japan Friendship School of Clinical Medicine, Graduate School of Capital Medical University, Beijing 100029, China
| | - D Xiao
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - Chen Wang
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| |
Collapse
|
2
|
Qiao J, Qin R, Feng ZZ, Wu JF. [Gastric-type extremely well-differentiated adenocarcinoma of the stomach with lymph node metastasis: report of a case]. Zhonghua Bing Li Xue Za Zhi 2021; 50:1401-1403. [PMID: 34865438 DOI: 10.3760/cma.j.cn112151-20210607-00417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- J Qiao
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| | - R Qin
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| | - Z Z Feng
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| | - J F Wu
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| |
Collapse
|
3
|
Qin R, Shi SS, Niu CL, Li ZJ, Diao H, Zhang RY. [Esophageal submucosal gland duct adenoma: report of a case]. Zhonghua Bing Li Xue Za Zhi 2021; 50:820-822. [PMID: 34405625 DOI: 10.3760/cma.j.cn112151-20201109-00834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- R Qin
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - S S Shi
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - C L Niu
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - Z J Li
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - H Diao
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - R Y Zhang
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| |
Collapse
|
4
|
Qin R, Wang H, Yan A. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods. SAR QSAR Environ Res 2021; 32:411-431. [PMID: 33896285 DOI: 10.1080/1062936x.2021.1910862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 03/27/2021] [Indexed: 06/12/2023]
Abstract
Leukotriene A4 hydrolase (LTA4H) is an important anti-inflammatory target which can convert leukotriene A4 (LTA4) into pro-inflammatory substance leukotriene B4 (LTB4). In this paper, we built 18 classification models for 463 LTA4H inhibitors by using support vector machine (SVM), random forest (RF) and K-Nearest Neighbour (KNN). The best classification model (Model 2A) was built from RF and MACCS fingerprints. The prediction accuracy of 88.96% and the Matthews correlation coefficient (MCC) of 0.74 had been achieved on the test set. We also divided the 463 LTA4H inhibitors into six subsets using K-Means. We found that the highly active LTA4H inhibitors mostly contained diphenylmethane or diphenyl ether as the scaffold and pyridine or piperidine as the side chain. In addition, six quantitative structure-activity relationship (QSAR) models for 172 LTA4H inhibitors were built by multiple linear regression (MLR) and SVM. The best QSAR model (Model 6A) was built by using SVM and CORINA Symphony descriptors. The coefficients of determination of the training set and the test set were equal to 0.81 and 0.79, respectively. Classification and QSAR models could be used for subsequent virtual screening, and the obtained fragments that were important for highly active inhibitors would be helpful for designing new LTA4H inhibitors.
Collapse
Affiliation(s)
- R Qin
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, Beijing, P. R. China
| | - H Wang
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, Beijing, P. R. China
| | - A Yan
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, Beijing, P. R. China
| |
Collapse
|
5
|
Burns E, Qin R, Metry D. Idiopathic Facial Aseptic Granuloma in an older child: A case report in a pre-adolescent boy. Pediatr Dermatol 2020; 37:1167-1168. [PMID: 32767587 DOI: 10.1111/pde.14314] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 05/11/2020] [Accepted: 07/08/2020] [Indexed: 11/29/2022]
Abstract
Idiopathic facial aseptic granuloma (IFAG) is an uncommon, benign lesion that presents in the pediatric population. The diagnosis is classically associated with preschool-aged children. Herein, we present a case of IFAG in a pre-adolescent boy, emphasizing the importance of diagnostic consideration in older children.
Collapse
Affiliation(s)
- Emily Burns
- Baylor College of Medicine, Houston, TX, USA
| | - Rosie Qin
- Department of Dermatology, Baylor College of Medicine, Houston, TX, USA
| | - Denise Metry
- Department of Dermatology, Baylor College of Medicine, Houston, TX, USA.,Department of Dermatology, Texas Children's Hospital, Houston, TX, USA
| |
Collapse
|
6
|
Wei M, Shi S, Xu J, Shen B, Mou Y, Qin R, Fang W, Chen R, Wang W, Shao C, Yu X. Simultaneous resection of pancreatic cancer and liver oligometastases after induction chemotherapy in stage IV patients: An open-label prospective randomized multicenter phase III trial (CSPAC-1). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
He SJ, Qin R, Wang W, Zhang RY. [Clinicopathological characteristics and research progress of neuroendocrine adenoma of the middle ear]. Zhonghua Bing Li Xue Za Zhi 2019; 48:749-752. [PMID: 31495105 DOI: 10.3760/cma.j.issn.0529-5807.2019.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S J He
- Clinical Medical College, Jining Medical University of Shandong, Jining 272000, China
| | - R Qin
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, China
| | - W Wang
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, China
| | - R Y Zhang
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, China
| |
Collapse
|
8
|
Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol 2019; 29:352-360. [PMID: 29069303 DOI: 10.1093/annonc/mdx689] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known. Patients and methods In a prospective clinical trial, mCRPC patients underwent whole-exome sequencing (n = 82) and RNA sequencing (n = 75) of metastatic biopsies before initiating AA/P with the objective of identifying genomic alterations associated with resistance to AA/P. Primary resistance was determined at 12 weeks of treatment using criteria for progression that included serum prostate-specific antigen measurement, bone and computerized tomography imaging and symptom assessments. Acquired resistance was determined using the end point of time to treatment change (TTTC), defined as time from enrollment until change in treatment from progressive disease. Associations of genomic and transcriptomic alterations with primary resistance were determined using logistic regression, Fisher's exact test, single and multivariate analyses. Cox regression models were utilized for determining association of genomic and transcriptomic alterations with TTTC. Results At 12 weeks, 32 patients in the cohort had progressed (nonresponders). Median study follow-up was 32.1 months by which time 58 patients had switched treatments due to progression. Median TTTC was 10.1 months (interquartile range: 4.4-24.1). Genes in the Wnt/β-catenin pathway were more frequently mutated and negative regulators of Wnt/β-catenin signaling were more frequently deleted or displayed reduced mRNA expression in nonresponders. Additionally, mRNA expression of cell cycle regulatory genes was increased in nonresponders. In multivariate models, increased cell cycle proliferation scores (≥ 50) were associated with shorter TTTC (hazard ratio = 2.11, 95% confidence interval: 1.17-3.80; P = 0.01). Conclusions Wnt/β-catenin pathway activation and increased cell cycle progression scores can serve as molecular markers for predicting resistance to AA/P therapy.
Collapse
Affiliation(s)
- L Wang
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
| | - S M Dehm
- Masonic Cancer Center, University of Minnesota, Minneapolis, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA; Department of Urology, University of Minnesota, Minneapolis, USA
| | - D W Hillman
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - H Sicotte
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - W Tan
- Department of Medicine, Mayo Clinic, Jacksonville, USA
| | - M Gormley
- Janssen Research and Development, Spring House, Philadelphia, USA
| | - V Bhargava
- Janssen Research and Development, Spring House, Philadelphia, USA
| | - R Jimenez
- Department of Pathology and Lab Medicine, Mayo Clinic, Rochester, USA
| | - F Xie
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - P Yin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - S Qin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - F Quevedo
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - B A Costello
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - H C Pitot
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - T Ho
- Department of Medicine, Mayo Clinic, Scottsdale, USA
| | - A H Bryce
- Department of Medicine, Mayo Clinic, Scottsdale, USA
| | - Z Ye
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
| | - Y Li
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - P Eiken
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - P T Vedell
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - P Barman
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - B P McMenomy
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - T D Atwell
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - R E Carlson
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - M Ellingson
- Medical Genetics, Mayo Clinic, Rochester, USA
| | - B W Eckloff
- Medical Genome Facility, Mayo Clinic, Rochester, USA
| | - R Qin
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - F Ou
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - S N Hart
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - H Huang
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
| | - J Jen
- Medical Genome Facility, Mayo Clinic, Rochester, USA; Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, USA
| | - E D Wieben
- Medical Genome Facility, Mayo Clinic, Rochester, USA
| | - K R Kalari
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - R M Weinshilboum
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - L Wang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA.
| | - M Kohli
- Department of Oncology, Mayo Clinic, Rochester, USA.
| |
Collapse
|
9
|
Rosdahl JA, Rudd M, Benjamin R, Wiener JS, Sloane R, Brown A, Robert Lee W, Turner D, Qin R, Atwater AR. Effect of the Adoption of a Comprehensive Electronic Health Record on Graduate Medical Education: Perceptions of Faculty and Trainees. South Med J 2019; 111:476-483. [PMID: 30075473 DOI: 10.14423/smj.0000000000000847] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES Health systems are adopting electronic health records (EHRs). There are few studies on the effects of EHR implementation on graduate medical education. The authors sought to longitudinally assess perceptions of the impact of EHRs on graduate medical education during implementation and 2 years after implementation. METHODS A survey was distributed to faculty and trainees during the first year (2013) of adoption of the EHR system. A follow-up survey was distributed 2 years later (2015). The χ2 test was used to compare the quantitative responses, and factor analysis was conducted to identify correlations between items. Free text responses were analyzed qualitatively. RESULTS The initial survey (in 2013) included 290 faculty and 106 trainees; the follow-up survey (in 2015) included 353 faculty and 226 trainees. In 2013, respondents had a positive impression of EHRs. During the implementation phase, participants believed that face-to-face teaching was negatively affected (P = 0.001). Faculty believed EHRs had a negative effect on trainees' ability to take a history/conduct physical examinations (P = 0.002) and to formulate a differential diagnosis/plan independently (P = 0.003). In 2015, faculty opinions of the impact of the EHR remained unchanged; trainee responses were more positive than in 2013 in some areas. Qualitative analysis showed that the most frequent strategies to enhance the educational process were the development of EHR skills and improved chart access and note assistance. CONCLUSIONS Respondents remain positive about the EHR 2 years after implementation. Faculty remain concerned about its effect on the educational process, whereas residents appear more positive regarding the potential for EHRs to enhance their education.
Collapse
Affiliation(s)
- Jullia A Rosdahl
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - Mariah Rudd
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - Robert Benjamin
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - John S Wiener
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - Richard Sloane
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - Audrey Brown
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - W Robert Lee
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - David Turner
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - Rosie Qin
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| | - Amber Reck Atwater
- From the Departments of Ophthalmology, Pediatrics, Radiation Oncology, and Dermatology, Duke Center for the Study of Aging and Human Development, and Duke Office of Clinical Research, Duke University Medical Center, Durham, North Carolina, and the Virginia Tech Carilion School of Medicine, Roanoke
| |
Collapse
|
10
|
Huang D, Li ZS, Fan XS, Wu HM, Liu JP, Sun WY, Li SS, Hou YY, Nie X, Li J, Qin R, Guo LC, Xu JH, Zhang HZ, Sun MM, Guo QN, Yang YH, Liu YH, Qin Y, Zhang LJ, Li JH, Zhang ZH, Gao P, Li YJ, Sheng WQ. [HER2 status in gastric adenocarcinoma of Chinese: a multicenter study of 40 842 patients]. Zhonghua Bing Li Xue Za Zhi 2018; 47:822-826. [PMID: 30423604 DOI: 10.3760/cma.j.issn.0529-5807.2018.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigation HER2 status in gastric adenocarcinoma of Chinese and contributing factors to the HER2 expression. Methods: HER2 status of 40 842 gastric adenocarcinomas and clinical data were retrospectively collected from 23 hospitals dated from 2013 to 2016. The association between HER2 positivity and clinicopathologic features was analyzed. Results: Of the 40 842 patients the median age was 62 years, the male female ratio was 2.6∶1.0. The rate of HER2 positivity was 8.8% (3 577/40 842). HER2 expression was related to the tissue type, tumor location, Lauren classification and tumor differentiation (P values: 0.009, 0.001, <0.01 and <0.01, respectively). Different HER2 expression status was observed between primary and recurrent tumors in 7.6% (48/635) cases. The rates of HER2 positivity ranged from 2% to 10% among different institutions. The rates of HER2 FISH amplification were dramatically different among the 23 hospitals (0-100%) with an average rate of 10% (810/8 156) in patients with HER2 IHC 2+ . Conclusions: HER2 expression is associated with clinicopathologic characteristics. HER2 re-assessment of tumor tissue and use of in situ hybridization techniques increase HER2 positivity. The current retrospective study should reflect the HER2 status in gastric adenocarcinoma of Chinese patients.
Collapse
Affiliation(s)
- D Huang
- Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Cater SW, Yoon SC, Lowell DA, Campbell JC, Sulioti G, Qin R, Jiang B, Grimm LJ. Bridging the Gap: Identifying Global Trends in Gender Disparity Among the Radiology Physician Workforce. Acad Radiol 2018; 25:1052-1061. [PMID: 29398433 DOI: 10.1016/j.acra.2017.12.021] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 12/14/2017] [Accepted: 12/25/2017] [Indexed: 11/28/2022]
Abstract
RATIONALE AND OBJECTIVES Women make up half of American medical school graduates, but remain underrepresented among radiologists. This study sought to determine whether workforce gender disparities exist in other countries, and to identify any country-specific indices associated with increased female representation. MATERIALS AND METHODS In this cross-sectional study, 95 professional radiology organizations in 75 countries were contacted via email to provide membership statistics, including proportion of female members, female members aged 35 or under, and women in society leadership positions. Country-specific metrics collected included gross domestic product, Gini index, percent female medical school enrollment, and Gender Development Index for the purposes of univariate multiple regression analysis. RESULTS Twenty-nine organizations provided data on 184,888 radiologists, representing 26 countries from Europe (n = 12), North America (n = 2), Central/South America (n = 6), Oceania (n = 2), Asia (n = 3), and Africa (n = 1) for a response rate of 34.7% (26/75). Globally, 33.5% of radiologists are female. Women constitute a higher proportion of younger radiologists, with 48.5% of radiologists aged 35 or under being female. Female representation in radiology is lowest in the United States (27.2%), highest in Thailand (85.0%), and most variable in Europe (mean 40.1%, range 28.8%-68.9%). The proportion of female radiologists was positively associated with a country's Gender Development Index (P = .006), percent female medical student enrollment (P = .001), and Gini index (P = .002), and negatively associated with gross domestic product (P = .03). CONCLUSIONS Women are underrepresented in radiology globally, most notably in the United States. Countries with greater representation of women had higher gender equality and percent female medical school enrollment, suggesting these factors may play a role in the gender gap.
Collapse
Affiliation(s)
- Sarah Wallace Cater
- Department of Radiology, Duke University Medical Center, 2301 Erwin Road, Box 3808, Durham, NC 27710.
| | - Sora C Yoon
- Department of Radiology, Duke University Medical Center, 2301 Erwin Road, Box 3808, Durham, NC 27710
| | - Dorothy A Lowell
- Department of Radiology, Duke University Medical Center, 2301 Erwin Road, Box 3808, Durham, NC 27710
| | | | - Gary Sulioti
- Duke University School of Medicine, Durham, North Carolina
| | - Rosie Qin
- Duke University School of Medicine, Durham, North Carolina
| | - Brian Jiang
- Duke University School of Medicine, Durham, North Carolina
| | - Lars J Grimm
- Department of Radiology, Duke University Medical Center, 2301 Erwin Road, Box 3808, Durham, NC 27710
| |
Collapse
|
12
|
Wu YJ, Qin R, He JM, Cao ZY, Dong LG, Yang B. [The influence of chemotherapy-induced leucopenia on the disease-free survival of gastric cancer patients after radical gastrectomy]. Zhonghua Yi Xue Za Zhi 2018; 98:1919-1922. [PMID: 29996282 DOI: 10.3760/cma.j.issn.0376-2491.2018.24.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the association between chemotherapy-induced leucopenia and patients' disease-free survival in gastric cancer patients who received radical gastrectomy. Methods: The clinical data of 273 gastric cancer patients who received radical gastrectomy and postoperative adjuvant chemotherapy between January, 2010 and December, 2015 in PLA 309(th) hospital was reviewed retrospectively. Results: A total of 195 (71.4%) patients experienced at least one time of leucopenia, while it was absent in the other 78 (28.6%) patients. The median disease-free survival of patients with or without leucopenia was 49.7 and 44.0 months respectively (P=0.009), leucopenia was an independent factor influencing patients' disease-free survival (HR=2.758, P=0.022), but there was no statistical difference between the disease-free survival of patients with different degrees and frequency of leucopenia (P=0.446, 0.123). Conclusion: Chemotherapy-induced leucopenia is a predictor of good prognosis for gastric cancer patients who receive radical gastrectomy.
Collapse
Affiliation(s)
- Y J Wu
- Department of General Surgery, PLA 309th Hospital, Beijing 100091, China
| | | | | | | | | | | |
Collapse
|
13
|
Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, Marzano AV, Wallach D, Kim K, Schadt C, Ormerod A, Fung MA, Steel A, Patel F, Qin R, Craig F, Williams HC, Powell F, Merleev A, Cheng MY. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol 2018; 154:461-466. [PMID: 29450466 DOI: 10.1001/jamadermatol.2017.5980] [Citation(s) in RCA: 243] [Impact Index Per Article: 40.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Importance Pyoderma gangrenosum is a rare inflammatory skin condition that is difficult to diagnose. Currently, it is a "diagnosis of exclusion," a definition not compatible with clinical decision making or inclusion for clinical trials. Objective To propose and validate diagnostic criteria for ulcerative pyoderma gangrenosum. Evidence Review Diagnostic criteria were created following a Delphi consensus exercise using the RAND/UCLA Appropriateness Method. The criteria were validated against peer-reviewed established cases of pyoderma gangrenosum and mimickers using k-fold cross-validation with methods of multiple imputation. Findings Delphi exercise yielded 1 major criterion-biopsy of ulcer edge demonstrating neutrophilic infiltrate-and 8 minor criteria: (1) exclusion of infection; (2) pathergy; (3) history of inflammatory bowel disease or inflammatory arthritis; (4) history of papule, pustule, or vesicle ulcerating within 4 days of appearing; (5) peripheral erythema, undermining border, and tenderness at ulceration site; (6) multiple ulcerations, at least 1 on an anterior lower leg; (7) cribriform or "wrinkled paper" scar(s) at healed ulcer sites; and (8) decreased ulcer size within 1 month of initiating immunosuppressive medication(s). Receiver operating characteristic analysis revealed that 4 of 8 minor criteria maximized discrimination, yielding sensitivity and specificity of 86% and 90%, respectively. Conclusions and Relevance This Delphi exercise produced 1 major criterion and 8 minor criteria for the diagnosis of ulcerative pyoderma gangrenosum. The criteria may serve as a guideline for clinicians, allowing for fewer misdiagnoses and improved patient selection for clinical trials.
Collapse
Affiliation(s)
- Emanual Maverakis
- Department of Dermatology, University of California, Davis, Sacramento
| | - Chelsea Ma
- Department of Dermatology, University of California, Davis, Sacramento
| | - Kanade Shinkai
- Department of Dermatology, University of California, San Francisco
| | - David Fiorentino
- Division of Immunology and Rheumatology, Department of Dermatology, Stanford University, Stanford, California
- Division of Immunology and Rheumatology, Department of Internal Medicine, Stanford University, Stanford, California
| | - Jeffrey P Callen
- Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Kentucky
- Associate Editor
| | - Uwe Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden, Dresden, Germany
| | - Angelo Valerio Marzano
- UOC di Dermatologia, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milano-Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milano, Italy
| | - Daniel Wallach
- Department of Dermatology, Paris Hospitals, Paris, France
| | - Kyoungmi Kim
- Division of Biostatistics, Department of Public Health Sciences, University of California, Davis
| | - Courtney Schadt
- Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Kentucky
| | - Anthony Ormerod
- Department of Dermatology, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom
| | - Maxwell A Fung
- Department of Dermatology, University of California, Davis, Sacramento
| | - Andrea Steel
- Department of Dermatology, University of California, Davis, Sacramento
| | - Forum Patel
- Department of Dermatology, University of California, Davis, Sacramento
| | - Rosie Qin
- Department of Dermatology, University of California, Davis, Sacramento
| | - Fiona Craig
- Department of Dermatology, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom
| | - Hywel C Williams
- Centre of Evidence Based Dermatology, King's Meadow Campus, University of Nottingham, United Kingdom
| | - Frank Powell
- Charles Institute of Dermatology, University College, Dublin, Ireland
| | - Alexander Merleev
- Department of Dermatology, University of California, Davis, Sacramento
| | - Michelle Y Cheng
- Department of Dermatology, University of California, Davis, Sacramento
| |
Collapse
|
14
|
Stujanna E, Murakoshi N, Tajiri K, Qin R, Feng D, Yonebayashi S, Ogura Y, Kimura T, Xu D, Aonuma K. P5381Rev-erb receptor agonist improves cardiac function through modulating inflammatory processes in myocardial infarction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Dunnick C, Mounessa J, Chapman S, Braunberger T, Qin R, Lipoff J, Dellavalle R. 367 Patient and provider satisfaction with teledermatology: A systematic review. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Zhang G, Zhu Y, Qin W, Yu L, Wu G, Ma S, Wang F, Qin R, Yang X, Tao K, Yue S, Zhao G, Yang Z, Yuan J, Dou K, Yuan J. Combined Kidney Transplantation and Splenic Fossa Auxiliary Heterotopic Liver Transplantation in a Highly Sensitized Recipient: A Case Report. Transplant Proc 2017; 48:3191-3196. [PMID: 27932179 DOI: 10.1016/j.transproceed.2016.09.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Revised: 08/23/2016] [Accepted: 09/01/2016] [Indexed: 12/20/2022]
Abstract
BACKGROUND Combined kidney and auxiliary orthotopic liver transplantation from the same donor is used to treat highly sensitized renal transplant recipients. Auxiliary liver can protect the transplanted kidney against hyperacute rejection. METHODS In the current case, combined kidney and splenic fossa auxiliary heterotopic liver transplantation was performed from the same donor for a highly sensitized recipient without preoperative preconditioning. No postoperative hyperacute rejection occurred. RESULTS Seven days after surgery, preexisting antibody levels rose and decreased after treatment; meanwhile, the function of transplanted kidney returned to normal. During 24 months of follow-up, the grafts showed good blood perfusion and functioned well. The levels of preexisting antibodies, donor-specific antibodies (DSA) and C1q-fixing human leukocyte antigen (C1q-HLA) antibodies, all decreased. CONCLUSIONS Combined kidney and splenic fossa auxiliary heterotopic liver transplantation can be used in renal transplantation for highly sensitized recipients.
Collapse
Affiliation(s)
- G Zhang
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - Y Zhu
- Department of Urology, Hanzhong Central Hospital, Shanxi, China
| | - W Qin
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - L Yu
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - G Wu
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - S Ma
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - F Wang
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - R Qin
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - X Yang
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - K Tao
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - S Yue
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - G Zhao
- Xijing Orthopedic Hospital of the Fourth Military Medical University, Shanxi, China
| | - Z Yang
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - J Yuan
- Department of Biochemistry, University of Washington, Seattle, Washington
| | - K Dou
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - J Yuan
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China.
| |
Collapse
|
17
|
Mounessa JS, Chapman S, Braunberger T, Qin R, Lipoff JB, Dellavalle RP, Dunnick CA. A systematic review of satisfaction with teledermatology. J Telemed Telecare 2017; 24:263-270. [PMID: 28350281 DOI: 10.1177/1357633x17696587] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background The two most commonly used modalities of teledermatology (TD) are store-and-forward (SF) and live-interactive (LI) TD. Existing studies have not compared these tools with respect to patient and provider satisfaction. Objective To systematically review all published studies of patient and provider satisfaction with SF and LI TD. Methods PubMed, EMBASE, and Cochrane databases were systematically searched for studies on provider or patient satisfaction with SF or LI TD between January 2000 and June 2016. Results Forty eligible studies were identified: 32 with SF TD, 10 with LI TD, and 2 evaluating both. With SF TD, 96% of studies assessing patient satisfaction and 82% of studies assessing provider satisfaction demonstrated satisfaction ( n = 24 and 17, respectively). With LI TD, 89% of studies assessing patient satisfaction and all studies assessing provider satisfaction revealed satisfaction (n = 9 and 6, respectively). Conclusion Patients and providers are satisfied with both SF and LI TD. Studies assessing satisfaction with LI have not been conducted in recent years, and have only been conducted in limited geographic patient populations. Further research assessing satisfaction with TD will help address any dissatisfaction with its uses and allow for increased support and funding of future programmes.
Collapse
Affiliation(s)
- Jessica S Mounessa
- 1 Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Stephanie Chapman
- 2 Michigan State University College of Human Medicine, Grand Rapids, MI, USA
| | | | - Rosie Qin
- 4 Duke University School of Medicine, Durham, NC, USA
| | - Jules B Lipoff
- 5 Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Robert P Dellavalle
- 1 Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.,6 Dermatology Service, Eastern Colorado Health Care System, US; Department of Veteran Affairs, Denver, CO, USA.,7 Department of Community and Behavioral Health, Colorado School of Public Health, Aurora, CO, USA
| | - Cory A Dunnick
- 1 Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.,6 Dermatology Service, Eastern Colorado Health Care System, US; Department of Veteran Affairs, Denver, CO, USA
| |
Collapse
|
18
|
Qin R, Cohen PR. Concurrent pyogenic granuloma and bullous impetigo of a pregnant woman's finger. Dermatol Online J 2017; 23:13030/qt0p22m4dg. [PMID: 28329529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Accepted: 03/22/2017] [Indexed: 06/06/2023] Open
Abstract
BACKGROUND Bullous impetigo is a superficial skininfection caused by Staphylococcus aureus (S.aureus). Pyogenic granuloma is a common benigntumor frequently associated with prior trauma.Bullous impetigo and pyogenic granuloma may occurin pregnant women. PURPOSE The features of a pregnant womanwith pyogenic granuloma and bullous impetigoconcurrently present in a lesion on her finger aredescribed. METHODS PubMed was used to search the followingterms: bullous impetigo, pregnancy, and pyogenicgranuloma. All papers were reviewed; relevantarticles, along with their references, were evaluatedResults: A red ulcerated nodule with a collaretteof epithelium around the tumor and surroundingbullae appeared on the fifth digit of the left hand of a31-year-old woman who was at 36 weeks gestation. Abacterial culture grew methicillin sensitive S. aureus.An excisional biopsy was performed. Histologicfindings revealed not only a benign vascular tumorwith an infiltrate of mixed inflammatory cells, butalso an intraepidermal blister. She received oralantibiotics and there was complete resolution of thefinger lesion and infection with preservation of digitfunction. CONCLUSION Albeit uncommon, pyogenic granulomaand bullous impetigo may concurrently occur in thesame lesion. Therapeutic intervention should focuson treating both the benign skin tumor and theinfection.
Collapse
Affiliation(s)
- Rosie Qin
- Department of Medicine, University of California San Diego, La Jolla, California.
| | | |
Collapse
|
19
|
Qin R, Cohen PR. Concurrent pyogenic granuloma and bullous impetigo of a pregnant woman’s finger. Dermatol Online J 2017. [DOI: 10.5070/d3233034303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
20
|
Abstract
The incidence of malignant melanoma (MM) continues to rise in the United States. While sun protection and full body skin examinations remain the mainstay of preventative care, chemoprevention of the deadly disease has become an increasingly popular field of study. In this focused review, we discuss current findings and analyze the risks and benefits of various agents investigated for the primary and secondary chemoprevention of MM. Such agents include topical retinoids, vitamins, and supplements, Polypodium leucotomas extracts, non-steroidal anti-inflammatory agents (NSAIDs), statins, sunscreens, and field therapy with topical imiquimod for primary and secondary chemoprevention. We further identify a need for expanded high quality human research on the topic.
Collapse
Affiliation(s)
- Jessica Mounessa
- Stony Brook University School of Medicine, 101 Nicolls Road, Stony Brook, NY, 11794, USA
- Department of Dermatology, University of Colorado Hospital, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - Talayesa Buntinx-Krieg
- University of Central Florida College of Medicine, 6850 Lake Nona Blvd, Orlando, FL, 32827, USA
| | - Rosie Qin
- Department of Medicine, University of San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA
| | - Cory A Dunnick
- Department of Dermatology, University of Colorado Hospital, 1665 Aurora Ct, Aurora, CO, 80045, USA
- Department of Dermatology, Denver VA Medical Center, 1055 Clermont St. #165, Denver, CO, 80220, USA
| | - Robert P Dellavalle
- Department of Dermatology, University of Colorado Hospital, 1665 Aurora Ct, Aurora, CO, 80045, USA.
- Department of Dermatology, Denver VA Medical Center, 1055 Clermont St. #165, Denver, CO, 80220, USA.
| |
Collapse
|
21
|
Zhang LJ, Wen Y, Zhu J, Qin R, Xi K. P-199THE NUMBER OF RESECTED LYMPH NODES IS ASSOCIATED WITH THE LONG-TERM SURVIVAL OUTCOME IN PATIENTS WITH T2N0 NON-SMALL CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Olson AC, Thomas S, Qin R, Singh B, Salama JK, Kirkpatrick J, Salama AK. Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. Melanoma Manag 2016; 3:177-186. [PMID: 30190887 DOI: 10.2217/mmt-2016-0004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Accepted: 03/17/2016] [Indexed: 02/07/2023] Open
Abstract
Purpose Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety. Methods Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival. Results We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI: 3.1-12.2). Overall survival was 23.4 months (95% CI: 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI: 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen: 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis. Conclusion SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.
Collapse
Affiliation(s)
- Adam C Olson
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.,Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
| | - Samantha Thomas
- Department of Biostatistics, Duke Cancer Institute, Durham, NC, USA.,Department of Biostatistics, Duke Cancer Institute, Durham, NC, USA
| | - Rosie Qin
- Duke University School of Medicine, Durham, NC, USA.,Duke University School of Medicine, Durham, NC, USA
| | - Bhavana Singh
- Department of Medicine, Duke University Medical Center, Durham, NC, USA.,Department of Medicine, Duke University Medical Center, Durham, NC, USA
| | - Joseph K Salama
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.,Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
| | - John Kirkpatrick
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.,Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
| | - April Ks Salama
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.,Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
| |
Collapse
|
23
|
Wen YS, Huang C, Zhang X, Qin R, Lin P, Rong T, Zhang LJ. Impact of metabolic syndrome on the survival of Chinese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus 2016; 29:607-13. [PMID: 26123618 DOI: 10.1111/dote.12376] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Metabolic syndrome (MetS) is associated with the risk of esophageal squamous cell carcinoma (ESCC). However, the impact of MetS on survival has not been evaluated. A retrospective review was performed on 596 consecutive Chinese patients with esophageal squamous cell carcinoma who received surgery between January 2005 and October 2007. The clinical data and pretreatment information related to MetS were reviewed. The impact of MetS on overall survival (OS) was estimated by Kaplan-Meier and Cox proportional hazards analyses. MetS was a significant and independent predictor for better survival in patients with resectable ESCC. The 3-year OS and 5-year OS for patients with and without MetS were 75.0% versus 57.8% and 65.1% versus 44.6%, respectively (P = 0.005 in the univariate analysis, P = 0.010 in multivariate analysis). However, there was no apparent influence of any single component of MetS on OS. The other independent prognostic factors identified in the univariate analysis included the following: gender, smoking status, alcohol use, the extent of radical surgical resection, T and N stage, and tumor differentiation. The results of the multivariate analysis included the extent of radical surgery resection, T and N stage, and tumor differentiation. MetS was also associated with greater tumor cell differentiation (P = 0.036). There was no association found between MetS status and postoperative complications. MetS is an independent prognostic factor for OS in patients with ESCC and is associated with better tumor cell differentiation.
Collapse
Affiliation(s)
- Y-S Wen
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - C Huang
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - X Zhang
- School of Medicine, University of Glasgow, Glasgow, UK
| | - R Qin
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - P Lin
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - T Rong
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - L-J Zhang
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| |
Collapse
|
24
|
Liu P, Zhao Y, Qin R, Mo S, Chen G, Gu L, Chevrier DM, Zhang P, Guo Q, Zang D, Wu B, Fu G, Zheng N. Photochemical route for synthesizing atomically dispersed palladium catalysts. Science 2016; 352:797-801. [DOI: 10.1126/science.aaf5251] [Citation(s) in RCA: 1199] [Impact Index Per Article: 149.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Accepted: 04/05/2016] [Indexed: 11/02/2022]
|
25
|
Abstract
Ipilimumab is the first immunotherapy shown to increase overall survival in patients with metastatic melanoma. Currently, there are no accepted guidelines for use of ipilimumab in organ transplant patients. There is only one report in the literature on successful administration of ipilimumab in two kidney transplant recipients. In this report, a heart transplant patient with metastatic melanoma was successfully treated with ipilimumab. He experienced no adverse drug reactions. However, after standard treatment with regimen of four doses at 3 mg/kg, he experienced disease progression. Here, we address concerns of organ rejection or ineffective treatment when using ipilimumab or other immune checkpoint inhibitors in patients who are chronically immunosuppressed.
Collapse
Affiliation(s)
- Rosie Qin
- School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.,School of Medicine, Duke University Medical Center, Durham, NC 27710, USA
| | - April Ks Salama
- Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA.,Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
| |
Collapse
|
26
|
|
27
|
Jimenez R, Sicotte H, Barman P, Sinnwell J, Eiken P, Atwell T, McMenomy B, Tan W, Wu K, Bryce A, Ho T, Pitot H, Quevedo J, Costello B, Dronca R, Moynihan T, Wang L, Qin R, Carlson R, Kohli M. 2523 Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate resistant prostate cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31342-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Kohli M, Tan W, Eiken P, McMenomy B, Atwell T, Carlson R, Campion M, Wang L, Costello B, Pitot H, Quevedo F, Ho T, Bryce A, Qin R, Paz-Fumagalli R, Moynihan T, Dronca R, Liu M. 2573 Impact of biopsy of metastases on circulating tumor cell (CTC) counts in castrate resistant prostate cancer (CRPC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31392-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
29
|
He JM, Pu YD, Wu YJ, Qin R, Zhang QJ, Sun YS, Zheng WW, Chen LP. Association between dietary intake of folate and MTHFR and MTR genotype with risk of breast cancer. Genet Mol Res 2014; 13:8925-31. [PMID: 25366783 DOI: 10.4238/2014.october.31.7] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We investigated the association between dietary intake of folate, vitamin B6, and the 5,10-methylenetetrahydrofolate reductase (MTHFR) genotype with breast cancer. A matched case-control study was conducted, and 413 patients with newly diagnosed and histologically confirmed breast cancer and 436 controls were recruited. Folate intake, vitamin B6, and vitamin B12 levels were calculated, and the MTHFR C677T and A1298C and MTR A2756G polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism. Breast cancer cases were generally older, older at first live birth, and younger at menarche, had a higher body mass index, were smokers, had higher energy intake, and more first-degree relatives with breast cancer as well as more live births compared to controls. With respect to energy intake, we found that higher energy intake were more likely to increase the risk of breast cancer. The MTHFR 667TT genotype was associated with a moderately increased risk of breast cancer when compared with the CC genotype, and a significant odds ratio (OR; 95% confidence interval, CI) was found (OR = 1.70, 95%CI = 1.06-2.73). Individuals carrying T allele were associated with higher risk of breast cancer when compared with C allele (OR = 1.34, 95%CI = 1.06-1.70). We did not find a significant effect of the MTHFR A1298C and MTR A2756G on the risk of breast cancer. We did not find any association between folate intake and MTHFR C677T polymorphisms. In conclusion, we found that the MTHFR C667T polymorphism is associated with the risk of breast cancer, indicating that this genotype plays a role in breast cancer development.
Collapse
Affiliation(s)
- J M He
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Y D Pu
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Y J Wu
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - R Qin
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Q J Zhang
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Y S Sun
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - W W Zheng
- General Surgery Department, Xinxiang Medical College, Weihui, China
| | - L P Chen
- General Surgery Department, Xinxiang Medical College, Weihui, China
| |
Collapse
|
30
|
Xu T, Wang H, Yan Y, Qin R, Jiang Y, Lu Y, Li W, Xia C, Chen J. O10.08 * HIGH G-PROTEIN-COUPLED RECEPTORS 65 (GPR65) EXPRESSION PREDICTS A POORER SURGICAL OUTCOME OF GLIOBLASTOMA PATIENTS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Zhang L, Li G, He GC, Zhu LL, Qin R, Jing SL. Isolation, characterization, and cross-transferability of microsatellite markers from the whitebacked planthopper (Sogatella furcifera). Genet Mol Res 2014; 13:6248-52. [PMID: 25158251 DOI: 10.4238/2014.august.15.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The whitebacked planthopper Sogatella furcifera (Horváth) (Hemiptera: Delphacidae) is one of the most harmful pests of rice. In this study, 18 polymorphic microsatellite markers were developed from S. furcifera genomic libraries using the fast isolation by amplified fragment length polymorphism of sequences containing repeat protocols. Microsatellite polymorphism was investigated using 32 individuals from one natural population. These 18 simple sequence repeat markers showed a number of alleles that ranged from 3 to 15 and had observed and expected heterozygosities that ranged from 0.094 to 0.871 and from 0.148 to 0.924, respectively. The high cross-species transferability of these markers was evaluated in three other planthopper species: Nilaparvata lugens, N. muiri China, and N. bakeri (Muir). These microsatellite markers will provide powerful tools for population genetic and ecological studies of this pest and its related species in the future.
Collapse
Affiliation(s)
- L Zhang
- Engineering Research Center of Protection and Utilization for Biological Resources in Minority Regions, South-Central University for Nationalities, Wuhan, Hubei, P.R. China
| | - G Li
- Engineering Research Center of Protection and Utilization for Biological Resources in Minority Regions, South-Central University for Nationalities, Wuhan, Hubei, P.R. China
| | - G C He
- State Key Laboratory of Hybrid Rice, College of Life Science, Wuhan University, Wuhan Hubei, P.R, China
| | - L L Zhu
- State Key Laboratory of Hybrid Rice, College of Life Science, Wuhan University, Wuhan Hubei, P.R, China
| | - R Qin
- Engineering Research Center of Protection and Utilization for Biological Resources in Minority Regions, South-Central University for Nationalities, Wuhan, Hubei, P.R. China
| | - S L Jing
- State Key Laboratory of Hybrid Rice, College of Life Science, Wuhan University, Wuhan Hubei, P.R, China
| |
Collapse
|
32
|
Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, Long L, Zhu XL, Xie CJ, Xu WL. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res 2014; 47:60-9. [PMID: 24519092 PMCID: PMC3932974 DOI: 10.1590/1414-431x20133324] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Accepted: 10/15/2013] [Indexed: 12/13/2022] Open
Abstract
MicroRNAs (miRNAs) are small RNA molecules that modulate gene expression implicated in cancer, which play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. The aim of this study was to investigate whether miR-30c mediated the resistance of breast cancer cells to the chemotherapeutic agent doxorubicin (ADR) by targeting tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ). miR-30c was downregulated in the doxorubicin-resistant human breast cancer cell lines MCF-7/ADR and MDA-MB-231/ADR compared with their parental MCF-7 and MDA-MB-231 cell lines, respectively. Furthermore, we observed that transfection of an miR-30c mimic significantly suppressed the ability of MCF-7/ADR to resist doxorubicin. Moreover, the anti-apoptotic gene YWHAZ was confirmed as a target of miR-30c by luciferase reporter assay, and further studies indicated that the mechanism for miR-30c on the sensitivity of breast cancer cells involved YWHAZ and its downstream p38 mitogen-activated protein kinase (p38MAPK) pathway. Together, our findings provided evidence that miR-30c was one of the important miRNAs in doxorubicin resistance by regulating YWHAZ in the breast cancer cell line MCF-7/ADR.
Collapse
Affiliation(s)
- Y Fang
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - H Shen
- Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - Y Cao
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - H Li
- Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - R Qin
- Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - Q Chen
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - L Long
- Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - X L Zhu
- Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - C J Xie
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - W L Xu
- Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| |
Collapse
|
33
|
Zhang P, Xiao H, Liu H, Qin R. Regulation of zinc transporter 3 and carbonic anhydrases 2 and 14 mRNA expression in the retina of rats affected by low dietary zinc. Genet Mol Res 2014; 13:963-71. [DOI: 10.4238/2014.february.19.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C, Hu J, Wang M, Qin R. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 2013; 109:3092-104. [PMID: 24169343 PMCID: PMC3859942 DOI: 10.1038/bjc.2013.655] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2013] [Revised: 09/05/2013] [Accepted: 10/01/2013] [Indexed: 12/31/2022] Open
Abstract
Background: The multidrug resistance and distant metastasis of cholangiocarcinoma result in high postoperative recurrence and low long-term survival rates. It has been demonstrated that the ectopic expression of miR-200 suppresses the multidrug resistance and metastasis of cancer. However, the expression and function of miR-200 in cholangiocarcinoma has not yet been described. Methods: In this study, we identified dysregulated microRNAs (miRNAs, miR) in cholangiocarcinoma tissue by microarray analysis, and subsequent real-time PCR and northern blot analyses validated the expression of candidate miR. We performed functional analyses and investigated the relationship between miR-200b/c expression and the properties of cholangiocarcinoma cells. A dual luciferase assay was applied to examine the effect of miRNAs on the 3′-UTR of target genes, and we demonstrated the function of the target gene by siRNA transfection identifying the downstream pathway via western blotting. Results: We found significantly downregulated expression of four miR-200 family members (miR-200a/b/c/429) and then confirmed that ectopic miR-200b/200c inhibits the migration and invasion of cholangiocarcinoma cells both in vitro and in vivo. We found that miR-200b/c influenced the tumourigenesis of cholangiocarcinoma cells including their tumour-initiating capacity, sphere formation, and drug resistance. We further found that miR-200b/c regulated migration and invasion capacities by directly targeting rho-kinase 2 and regulated tumorigenic properties by directly targeting SUZ12 (a subunit of a polycomb repressor complex). Conclusion: Our study shows that miR-200b/c has a critical role in the regulation of the tumorigenic and metastatic capacity of cholangiocarcinoma and reveals the probable underlying mechanisms.
Collapse
Affiliation(s)
- F Peng
- Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei 430030, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Qin R, Chen Z, Ding Y, Hao J, Hu J, Guo F. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 2013; 60:486-92. [PMID: 23790166 DOI: 10.4149/neo_2013_063] [Citation(s) in RCA: 132] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Cervical cancer remains an important public health problem worldwide. New and effective therapeutic strategies targeting cervical cancer are urgently needed. Long non-coding RNAs (lncRNAs) are newly identified regulators in tumorigenesis and tumor progression. To investigate the role of lncRNA MEG3 in the development of cervical cancer, we examined MEG3 expression in 18 pairs of cervical cancer and matched adjacent non-neoplastic tissues. Real-time quantitative RT-PCR (qRT-PCR) results showed high expression levels of MEG3 in non-neoplastic tissues, but markedly lower levels in cancer tissues. We further investigated whether the restoration of MEG3 expression might affect the proliferation of cervical carcinoma cells. Ectopic expression of MEG3 inhibited the proliferation of human cervical carcinoma cells HeLa and C-33A in vitro. On the other hand, knockdown of MEG3 promoted the growth of well-differentiated cervical carcinoma HCC94 cells. Further investigation into the mechanisms responsible for the growth inhibitory effects revealed that overexpression of MEG3 resulted in the induction of G2/M cell cycle arrest and apoptosis. These results identified an important role of MEG3 in the molecular etiology of cervical cancer and implicated the potential application of MEG3 in cervical cancer therapy.
Collapse
Affiliation(s)
- R Qin
- Department of Gynecology and Obstetrics, Xinxiang Medical University, Henan, China.
| | | | | | | | | | | |
Collapse
|
36
|
Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Cancer Gene Ther 2012; 19:839-44. [PMID: 23037808 PMCID: PMC3499676 DOI: 10.1038/cgt.2012.68] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The sodium iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to prostate cancer. We have developed a prostate tumor specific conditionally replicating adenovirus (CRAd) that expresses hNIS (Ad5PB_RSV-NIS). For radiovirotherapy to be effective in humans, the radioiodine dose administered in the pre-clinical animal model should scale to the range of acceptable doses in humans. We performed 131I dose-response experiments aiming to determine the dose required in mice to achieve efficient radiovirotherapy. Efficacy was determined by measuring tumor growth and survival times. We observed that individual tumors display disparate growth rates which preclude averaging within a treatment modality indicating heterogeneity of growth rate. We further show that a statistic and stochastic approach must be used when comparing the effect of an anti-cancer therapy on a cohort of tumors. Radiovirotherapy improves therapeutic value over virotherapy alone by slowing the rate of tumor growth in a more substantial manner leading to an increase in survival time. We also show that the radioiodine doses needed to achieve this increase scaled well within the current doses used for treatment of thyroid cancer in humans.
Collapse
Affiliation(s)
- M A Trujillo
- Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | |
Collapse
|
37
|
Abstract
OBJECTIVE Access to health care in rural areas of developing nations is hindered by both the lack of physicians and the preference of many physicians to practice in urban settings. As a result, rural patients often choose not to sacrifice wages or time to visit distant health care providers. A telemedicine system, Mashavu: Networked Health Solutions, designed to increase access to preprimary health care in rural areas, was field-tested in rural Kenya. This study aims to examine the reliability of the system compared to the traditional face-to-face method of health care delivery. METHOD Reliability of the telemedicine system was tested using a modified intraobserver concordance study. Community health workers operated the system in various remote locations. Patient health information including chief complaint, medical history, and vital statistics were sent via Internet to a consulting nurse. After patients completed the telemedicine consultation, they also met in-person with the same nurse. Subsequently, the nurse's advice during the in-person session was compared with his feedback provided through the telemedicine consultation. RESULTS When comparing the nurse's advice given through the telemedicine system with the advice given through more traditional face-to-face, in-person consultation, the nurse provided consistent medical feedback in 78.4% of the cases (n = 102). The nurse's advice regarding patient action (eg, clinical referrals or no further care necessary) was the same in 89.2% of the cases (n = 91). CONCLUSION The study found that this telemedicine system was able to provide patients with approximately the same quality of care and advice as if the patient had physically travelled to a clinic to see a nurse. In rural areas of developing nations where there are high logistical and economical barriers to accessing health care, this telemedicine system successfully increased the ease and lowered the cost of connecting rural patients with nurses to provide preprimary care.
Collapse
Affiliation(s)
- Rosie Qin
- The Pennsylvania State University, University Park, PA 16802, USA
| | | | | | | |
Collapse
|
38
|
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra9015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA9015 Background: Hot flashes are a common symptom during the menopause transition or following breast cancer treatment that can negatively impact the quality of life for many women. Preliminary data have suggested that flaxseed, a rich source of dietary lignans, may be a potentially effective treatment for hot flashes. Methods: A phase III randomized, placebo controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes. Postmenopausal women were randomly assigned to a flaxseed bar (providing 410 mg of lignans) for 6 weeks vs a placebo bar. Participants completed daily prospective, self report hot flash diaries during the baseline week and then began eating one study bar per day for 6 weeks, while continuing to record their daily hot flashes. The intra-patient difference in hot flash activity between baseline and the last treatment week was the primary endpoint. Side effects of the bars were evaluated through self report and CTC assessment. Results: Between October and December 2009, 188 women were enrolled onto this trial. Mean hot flash scores were reduced by 4.9 units in the flaxseed group and 3.5 in the placebo group (p=0.29). In both groups, a little over a third of the women received a 50% reduction in their hot flash scores. Only one side effect was significantly different between groups, that being grade 1 pruritis, which was more common (7%) in the placebo group versus 1% in the flaxseed group. Both groups reported increased abdominal distension, flatulence, diarrhea and nausea. Adherence and ability to detect treatment assignment did not differ between groups. Conclusions: The results of this trial do not support the use of 410 mg of flaxseed lignans for the reduction of hot flashes. The gastrointestinal side effects seen in both groups were likely due to the fiber content in the flaxseed and placebo bars.
Collapse
Affiliation(s)
- S. Pruthi
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - R. Qin
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - S. A. Terstriep
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - H. Liu
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - T. R. C. Shah
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - K. F. Tucker
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - M. J. Bury
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - R. L. Carolla
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - P. D. Steen
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - J. Vuky
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - D. L. Barton
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| |
Collapse
|
39
|
Morgan R, Oza AM, Qin R, Laumann KM, Mackay H, Strevel EL, Welch S, Sullivan D, Wenham RM, Chen HX, Doyle LA, Gandara DR, Erlichman C. A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Maples WJ, Picus J, Erlichman C. Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4548] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra9015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Dueck AC, Sargent DJ, Novotny PJ, Decker PA, Nelson H, Qin R, Sloan JA. Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Sun C, Cheng MC, Qin R, Liao DL, Chen TT, Koong FJ, Chen G, Chen CH. Identification and functional characterization of rare mutations of the neuroligin-2 gene (NLGN2) associated with schizophrenia. Hum Mol Genet 2011; 20:3042-51. [PMID: 21551456 DOI: 10.1093/hmg/ddr208] [Citation(s) in RCA: 98] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Schizophrenia is a severe chronic mental disorder with a high genetic component in its etiology. Several lines of study have suggested that synaptic dysfunction may underlie the pathogenesis of schizophrenia. Neuroligin proteins function as cell-adhesion molecules at post-synaptic membrane and play critical roles in synaptogenesis and synaptic maturation. In this study, we systemically sequenced all the exons and promoter region of neuroligin-2 (NLGN2) gene in a sample of 584 schizophrenia patients and 549 control subjects from Taiwan. In total, we identified 19 genetic variants, including six rare missense mutations such as R215H (one patient), V510M (two patients), R621H (one patient), A637T (two patients), P800L (one patient and one control) and A819S (one patient and one control). In silico analysis predicted that two patient-specific missense mutations, R215H and R621H, had damaging effect, whereas the other missense mutations were benign. Importantly, functional analysis with immunocytochemistry and electrophysiological recordings identified the R215H mutant as a loss-of-function mutant in inducing GABAergic synaptogenesis. Mechanistically, the synaptogenic deficiency of R215H mutant was due to its retention inside the endoplasmic reticulum and inability to be transported to cell membrane. Our study suggests that defects in GABAergic synapse formation in the brain may be an important contributing factor for the onset of schizophrenia. In the family study of this mutation, we found his elder brother also carried this mutation but did not have psychiatric symptoms, indicating that this mutation has incomplete penetrance, and thus the clinical relevance of this mutation should be interpreted with caution.
Collapse
Affiliation(s)
- Chicheng Sun
- Department of Biology, The Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, PA, USA
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot HC, Tan W, Erlichman C, Vaishampayan UN. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.259] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
259 Background: Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are produced by bladder cancer cell lines in vitro and expressed in human tumor tissues. Preclinical studies have also shown that bladder cancer cell lines express VEGF receptor 1 and 2 on their surface membrane. Pazopanib is a vascular endothelial receptor tyrosine kinase inhibitor with anti-angiogenesis and antitumor activity in several preclinical models. A two-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib administered to patients with metastatic, urothelial carcinoma. Methods: Patients with one prior systemic therapy for recurrent, metastatic urothelial carcinoma were eligible. Patients received pazopanib at a dose of 800 mg orally daily for 4 week cycle. Results: Nineteen patients were enrolled. Median age was 66 years, with > 89% of patients presenting poorly differentiated bladder cancer. Adverse event data is available on 18 patients. No grade 4 or 5 events have been experienced. Nine patients have experienced 11 grade 3 adverse events of which 7 were deemed at least possibly related to treatment. Most common toxicities were anemia, thrombocytopenia, leucopenia and fatigue. For stage 1, none of the first 16 evaluable patients were deemed success (CR or PR) by the RECIST criteria during the first four 4-week cycles of treatment. Median progression- free survival was 1.9 months. This met the futility stopping rule of interim analysis, and therefore, the trial was recommended to be permanently closed. Correlative studies including measurement of VEGF levels in archived tissues and blood are pending. Conclusions: Pazopanib did not show activity in urothelial carcinoma patients. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies. [Table: see text]
Collapse
Affiliation(s)
- R. Pili
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - R. Qin
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - P. J. Flynn
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - J. Picus
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - M. Millward
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - W. M. Ho
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - H. C. Pitot
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - W. Tan
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - C. Erlichman
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - U. N. Vaishampayan
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| |
Collapse
|
45
|
Wang H, Ni L, Yu C, Shi L, Qin R. Utilizing spiral computerized tomography during the removal of a fractured endodontic instrument lying beyond the apical foramen. Int Endod J 2010; 43:1143-51. [PMID: 21039622 DOI: 10.1111/j.1365-2591.2010.01780.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM To present a case that used spiral computerized tomography (CT) to locate and successfully remove a fractured endodontic instrument lying beyond the apical foramen using a surgical approach. SUMMARY The fracture of an endodontic instrument beyond the apical foramen is rare. In this case report, after an attempt to remove a fractured instrument failed, a multi-slice spiral computerized tomography (MSCT) was used for diagnosis and treatment planning. The fractured segment was precisely located and found in the soft tissue and successfully removed by surgery. For the successful removal of a fractured endodontic instrument beyond the apical foramen, the following are necessary: (i) knowledge of the cause of fracture and how to plan treatment; (ii) determining the precise location of the fractured segment using CT; and 3) skilful operation. KEY LEARNING POINTS • Fractured endodontic instruments might lie within the soft tissue. • Computerized tomography is an effective diagnostic aid for localizing the precise position of fractured instruments.
Collapse
Affiliation(s)
- H Wang
- Department of Operative Dentistry and Endodontics Department of Oral Radiology Department of Oral and Maxillofacial Surgery School of Stomatology, Fourth Military Medical University, Xi'an, China
| | | | | | | | | |
Collapse
|
46
|
Wang D, Gao S, Qin R, Browne G. Lateral movement of soil fumigants 1,3-dichloropropene and chloropicrin from treated agricultural fields. J Environ Qual 2010; 39:1800-1806. [PMID: 21043285 DOI: 10.2134/jeq2009.0474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The soil fumigants 1,3-dichloropropene (1,3-D) and chloropicrin (CP) are often used for controlling soil-borne plant pathogens and parasitic nematodes before reestablishing new vineyards and orchards. To evaluate crop safety and environmental risks with the replant fumigation, four field experiments were performed over 2 yr to examine 1,3-D and CP lateral movement away from the treated fields. Shank injection with or without a virtually impermeable film (V1F) was used in two vineyard fumigation experiments, and spot drip application without tarp cover was used in two orchard experiments. Results showed that 1,3-D and CP gases moved laterally to 6 m from the treated fields when the fumigants were applied by shank injection. The maximum 1,3-D or CP soil gas concentration at 6 m was approximately 10 ng cm(-3) when the fumigated plot was not cover with a tarp. With VIF, the measured maximum concentration increased to approximately 100 ng cm(-3). In the spot drip application, maximum 1,3-D and CP gas concentrations reached approximately 100 ng cm(-3) but at 1.5 m radial distance from the point of fumigant injection.
Collapse
Affiliation(s)
- D Wang
- USDA-ARS, Water Management Research Unit, San Joaquin Valley Agricultural Sciences Center, Parlier, CA 93648, USA.
| | | | | | | |
Collapse
|
47
|
Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Oursler M, Marks R, Haluska P, Molina JR, Koch K. Phase I trial of dasatinib (D) and lapatinib (L). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Wolf SL, Qin R, Menon SP, Rowland KM, Kugler JW, Flynn PJ, Christian D, Satele D, Berenberg JL, Loprinzi CL. Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Jones JM, Qin R, Bardia A, Linquist B, Wolf SL, Loprinzi CL. Prochlorperazine and 5HT3 antagonists for the treatment of breakthrough chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther 2010; 17:1325-32. [PMID: 20428214 PMCID: PMC2914818 DOI: 10.1038/gt.2010.63] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The sodium iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the sodium-iodide symporter (NIS) gene into prostate, colon, and breast cancer cells using adenoviral vectors. To improve vector efficiency we have developed a conditionally replicating adenovirus (CRAd) in which the E1a gene is driven by the prostate specific promoter, Probasin and the cassette RSV promoter-human NIScDNA-bGH polyA replaces the E3 region (CRAd Ad5PB_RSV-NIS). In vitro infection of the prostate cancer cell line LnCaP resulted in virus replication, cytolysis, and release of infective viral particles. Conversely, the prostate cancer cell line PC-3 (androgen receptor negative) and the pancreatic cancer cell line Panc-1 were refractory to the viral cytopathic effect and did not support viral replication. Radioiodine uptake was readily measurable in LnCaP cells infected with Ad5PB_RSV-NIS 24 hours post-infection, confirming NIS expression. In vivo, LnCaP tumor xenografts in nude mice injected intratumorally with Ad5PB_RSV_NIS CRAd expressed NIS actively as evidenced by 99Tc uptake and imaging. Administration of therapeutic 131I after virus injection significantly increased survival probability in mice carrying xenografted LnCaP tumors compared to virotherapy alone. The data indicate that Ad5PB_RSV_NIS replication is stringently restricted to androgen positive prostate cancer cells and results in effective NIS expression and uptake of radioiodine. This construct may allow multimodal therapy, combining cytolytic virotherapy with radioiodine treatment, to be developed as a novel treatment for prostate cancer.
Collapse
Affiliation(s)
- M A Trujillo
- Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | |
Collapse
|